fangchinoline has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Jiang, F; Li, Z; Piao, D; Ren, S; Zhang, A; Zhang, Z; Zhu, Y | 1 |
| Pang, D; Xing, ZB; Yao, L; Zhang, GQ; Zhang, XY; Zhang, YX | 1 |
2 other study(ies) available for fangchinoline and Adenocarcinoma
| Article | Year |
|---|---|
Fangchinoline exerts antitumour activity by suppressing the EGFR‑PI3K/AKT signalling pathway in colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drugs, Chinese Herbal; ErbB Receptors; Female; Humans; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Fangchinoline inhibits breast adenocarcinoma proliferation by inducing apoptosis.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Benzylisoquinolines; Breast Neoplasms; Caspases; Cell Line, Tumor; Cytochromes c; DNA Fragmentation; Drugs, Chinese Herbal; Female; Gene Expression Regulation, Neoplastic; Humans; Proto-Oncogene Proteins c-bcl-2; Stephania tetrandra | 2011 |